camostat has been researched along with Anorexia in 1 studies
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.
Anorexia: The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Voigt, JP | 1 |
| Wenz, D | 1 |
| Voits, M | 1 |
| Fink, H | 1 |
1 other study available for camostat and Anorexia
| Article | Year |
|---|---|
Does increased endogenous CCK interact with serotonin to reduce food intake in rats?
Topics: Animals; Anorexia; Body Weight; Cholecystokinin; Dose-Response Relationship, Drug; Drug Interactions | 2000 |